Key result
Oral anti-PCSK9 molecules advance in clinical development as alternatives to injectable lipid-lowering therapies.
Answers are grounded in this paper and cite their sources.
The development of oral anti-PCSK9 molecules could overcome the cost and administration barriers of current injectable PCSK9 inhibitors for managing hypercholesterolemia.
Pharmacological inhibition of Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) have been firmly established to be an effective approach to reduce low-density lipoprotein (LDL) cholesterol levels and cardiovascular events. Subcutaneous administration of monoclonal antibodies (evolocumab and alirocumab) every 2 or 4 weeks determined a 60 % reduction of LDL cholesterol levels, while the GalNac-siRNA anti PCSK9 (inclisiran) provided an effective lipid lowering activity (-50 %) after an initial subcutaneous dose, repeated after 3 months and followed by a maintenance dose every 6 months. Although these two approaches have the potentiality to bring the majority of patients at high and very-high cardiovascular risk to the appropriate LDL cholesterol targets, their cost and subcutaneous administration represent a strong limitation for their large-scale use. These problems could be overcome by the development of small chemical molecules anti PCSK9 as oral therapy for controlling hypercholesterolemia. In the present review, we summarized the pharmacological properties of oral anti PCSK9 molecules that are currently under clinical development (DC371739, CVI-LM001, and AZD0780), including the mimetic peptides enlicitide decanoate (MK-0616) and NNC0385-0434.
No takes yet. Share an insight, caveat, or question.
Ferri et al. (2024) conducted a review in Hypercholesterolemia. Oral anti-PCSK9 molecules was evaluated. Oral anti-PCSK9 molecules, including DC371739, CVI-LM001, AZD0780, and MK-0616, are currently under clinical development to provide an alternative to injectable PCSK9 inhibitors for controlling hypercholesterolemia.
Synapse has enriched 10 related papers. Consider them for comparative context: